<p>Friedenthal Financial 在第三季度购买了 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免费报告) 的新股份，根据该公司最近向 SEC 的披露，该基金购买了 1,657 股公司股票，价值约为 1,059,000 美元。</p>
<p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
<ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了对该公司的持股。STF Management LP 在第二季度将其在 IDEXX Laboratories 的持股提高了 1.3%。STF Management LP 目前拥有 1,240 股公司股票，价值 665,000 美元，在此期间又购买了 16 股。Clearstead Trust LLC 在第二季度将其在 IDEXX Laboratories 的股份增加了 1.1%。Clearstead Trust LLC 目前拥有 1,515 股公司股票，价值 813,000 美元，在此期间又购买了 16 股。Stratos Wealth Partners LTD. 在第二季度将其在 IDEXX Laboratories 的股份提高了 1.7%。Stratos Wealth Partners LTD. 目前拥有 1,051 股公司股票，价值 564,000 美元，在上个季度又购买了 18 股。Red Spruce Capital LLC 在第二季度将其在 IDEXX Laboratories 的股份提高了 1.1%。Red Spruce Capital LLC 目前拥有 1,701 股公司股票，价值 912,000 美元，在此期间又获得了 19 股。最后，Huntington National Bank 在第二季度将其在 IDEXX Laboratories 的持股提高了 0.5%。Huntington National Bank 目前拥有 3,651 股公司股票，价值 1,958,000 美元，在上个季度又获得了 19 股。机构投资者持有公司 87.84% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对 IDXX 股票发表了评论。Wall Street Zen 在 11 月 29 日的报告中将 IDEXX Laboratories 的评级从 &#34;强买入&#34; 下调至 &#34;买入&#34;。Stifel Nicolaus 在 11 月 3 日的报告中对 IDEXX Laboratories 设定了 775.00 美元的目标价。Weiss Ratings 在周一的研究报告中将 IDEXX Laboratories 的评级从 &#34;买入 (b-)&#34; 下调至 &#34;持有 (c+)&#34;。摩根大通在 11 月 4 日的研究报告中将 IDEXX Laboratories 的目标价从 675.00 美元提高至 775.00 美元，并给予该股票 &#34;超配&#34; 的评级。最后，瑞银集团在 11 月 4 日的报告中将 IDEXX Laboratories 的目标价从 710.00 美元提高至 750.00 美元，并给予公司 &#34;中性&#34; 的评级。七位分析师对该股票给予了买入评级，四位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，IDEXX Laboratories 目前的平均评级为 &#34;适度买入&#34;，共识目标价为 763.50 美元。</p>
<p><strong>查看我们关于 IDXX 的最新研究报告</strong></p>
<h2>IDEXX Laboratories 股价下跌 2.8%</h2>
<p>NASDAQ:IDXX 周三开盘价为 682.31 美元。该公司的速动比率为 0.87，流动比率为 1.18，债务与股本比率为 0.24。IDEXX Laboratories, Inc. 的一年低点为 356.14 美元，一年高点为 769.98 美元。该公司的市值为 544.8 亿美元，市盈率为 54.11，市盈增长比率为 4.19，贝塔值为 1.67。该股票的 50 日简单移动平均线为 692.65 美元，200 日简单移动平均线为 629.36 美元。</p>
<p>IDEXX Laboratories (NASDAQ:IDXX - 获取免费报告) 最近在 11 月 3 日发布了季度财报。该公司报告每股收益 (EPS) 为 3.22 美元，超出市场共识预期的 3.14 美元，超出 0.08 美元。IDEXX Laboratories 的股本回报率为 67.78%，净利润率为 24.65%。该公司本季度的收入为 11.1 亿美元，而市场共识预期为 10.7 亿美元。在去年同期，该公司每股收益为 2.80 美元。与去年同期相比，该公司的季度收入增长了 13.3%。IDEXX Laboratories 已将其 2025 财年的指引设定为每股收益 12.810-13.010 美元。卖方分析师预测 IDEXX Laboratories, Inc. 今年将发布 11.93 美元的每股收益。</p>
<h2>IDEXX Laboratories 的内部活动</h2>
<p>在相关消息中，执行副总裁 Nimrata Hunt 于 11 月 7 日星期五出售了 9,425 股公司的股票。该股票以平均价格 703.34 美元出售，总价值为 6,628,979.50 美元。交易完成后，该执行副总裁持有 21,149 股公司股票，价值约为 14,874,937.66 美元。这笔交易代表其持股减少了 30.83%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有公司 0.98% 的股票。</p>
<h2>关于 IDEXX Laboratories</h2>
<p>(免费报告)</p>
<p>IDEXX Laboratories, Inc NASDAQ: IDXX 是一家全球开发、制造和提供诊断产品和服务的公司，主要面向动物健康、水质检测和食品安全市场。公司总部位于缅因州韦斯特布鲁克，提供临床诊断仪器、消耗品、参考实验室测试和实践管理工具，支持全球的兽医、畜牧和乳制品生产商以及公用事业和食品生产商。</p>
<p>IDEXX 的产品组合包括用于兽医诊所快速诊断的即时检测和免疫测定、临床化学和血液学分析仪、自动化尿液分析系统以及数字诊断解决方案。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票比 IDEXX Laboratories 更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
<p><strong>想知道其他对冲基金持有 IDXX 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 IDEXX Laboratories, Inc.（NASDAQ:IDXX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
<p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 IDEXX Laboratories 并不在名单上。</p>
<p>虽然 IDEXX Laboratories 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IDEXX实验室

<p>Friedenthal Financial 在第三季度收购了 1,657 股 IDEXX Laboratories，价值 1,059,000 美元。分析师对 IDEXX 的评级不一，普遍目标价为 763.50 美元。该股票开盘价为 682.31 美元，市值为 544.8 亿美元。IDEXX 报告本季度每股收益为 3.22 美元，超出预期，并将 2025 财年的指导目标设定为每股收益 12.810-13.010 美元</p>

<p>Friedenthal Financial bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,657 shares of the company's stock, valued at approximately $1,059,000.</p>
<div class="lb-trans"><p>Friedenthal Financial 在第三季度购买了 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免费报告) 的新股份，根据该公司最近向 SEC 的披露，该基金购买了 1,657 股公司股票，价值约为 1,059,000 美元。</p>
</div><p>Get <strong>IDEXX Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently modified their holdings of the business. STF Management LP lifted its holdings in IDEXX Laboratories by 1.3% in the second quarter. STF Management LP now owns 1,240 shares of the company's stock worth $665,000 after purchasing an additional 16 shares during the period. Clearstead Trust LLC increased its stake in IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company's stock valued at $813,000 after buying an additional 16 shares during the period. Stratos Wealth Partners LTD. raised its position in shares of IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company's stock worth $564,000 after buying an additional 18 shares in the last quarter. Red Spruce Capital LLC lifted its stake in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company's stock worth $912,000 after acquiring an additional 19 shares during the period. Finally, Huntington National Bank boosted its holdings in shares of IDEXX Laboratories by 0.5% in the second quarter. Huntington National Bank now owns 3,651 shares of the company's stock valued at $1,958,000 after acquiring an additional 19 shares in the last quarter. Institutional investors own 87.84% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对该公司的持股。STF Management LP 在第二季度将其在 IDEXX Laboratories 的持股提高了 1.3%。STF Management LP 目前拥有 1,240 股公司股票，价值 665,000 美元，在此期间又购买了 16 股。Clearstead Trust LLC 在第二季度将其在 IDEXX Laboratories 的股份增加了 1.1%。Clearstead Trust LLC 目前拥有 1,515 股公司股票，价值 813,000 美元，在此期间又购买了 16 股。Stratos Wealth Partners LTD. 在第二季度将其在 IDEXX Laboratories 的股份提高了 1.7%。Stratos Wealth Partners LTD. 目前拥有 1,051 股公司股票，价值 564,000 美元，在上个季度又购买了 18 股。Red Spruce Capital LLC 在第二季度将其在 IDEXX Laboratories 的股份提高了 1.1%。Red Spruce Capital LLC 目前拥有 1,701 股公司股票，价值 912,000 美元，在此期间又获得了 19 股。最后，Huntington National Bank 在第二季度将其在 IDEXX Laboratories 的持股提高了 0.5%。Huntington National Bank 目前拥有 3,651 股公司股票，价值 1,958,000 美元，在上个季度又获得了 19 股。机构投资者持有公司 87.84% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts recently commented on IDXX shares. Wall Street Zen cut IDEXX Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 29th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings cut IDEXX Laboratories from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a research note on Monday. JPMorgan Chase &amp; Co. boosted their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 4th. Finally, UBS Group upped their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a &#34;neutral&#34; rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $763.50.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 IDXX 股票发表了评论。Wall Street Zen 在 11 月 29 日的报告中将 IDEXX Laboratories 的评级从 &#34;强买入&#34; 下调至 &#34;买入&#34;。Stifel Nicolaus 在 11 月 3 日的报告中对 IDEXX Laboratories 设定了 775.00 美元的目标价。Weiss Ratings 在周一的研究报告中将 IDEXX Laboratories 的评级从 &#34;买入 (b-)&#34; 下调至 &#34;持有 (c+)&#34;。摩根大通在 11 月 4 日的研究报告中将 IDEXX Laboratories 的目标价从 675.00 美元提高至 775.00 美元，并给予该股票 &#34;超配&#34; 的评级。最后，瑞银集团在 11 月 4 日的报告中将 IDEXX Laboratories 的目标价从 710.00 美元提高至 750.00 美元，并给予公司 &#34;中性&#34; 的评级。七位分析师对该股票给予了买入评级，四位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，IDEXX Laboratories 目前的平均评级为 &#34;适度买入&#34;，共识目标价为 763.50 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on IDXX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IDXX 的最新研究报告</strong></p>
</div><h2>IDEXX Laboratories Trading Down 2.8%</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 股价下跌 2.8%</h2>
</div><p>NASDAQ:IDXX opened at $682.31 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The firm has a market capitalization of $54.48 billion, a price-to-earnings ratio of 54.11, a price-to-earnings-growth ratio of 4.19 and a beta of 1.67. The stock has a fifty day simple moving average of $692.65 and a 200 day simple moving average of $629.36.</p>
<div class="lb-trans"><p>NASDAQ:IDXX 周三开盘价为 682.31 美元。该公司的速动比率为 0.87，流动比率为 1.18，债务与股本比率为 0.24。IDEXX Laboratories, Inc. 的一年低点为 356.14 美元，一年高点为 769.98 美元。该公司的市值为 544.8 亿美元，市盈率为 54.11，市盈增长比率为 4.19，贝塔值为 1.67。该股票的 50 日简单移动平均线为 692.65 美元，200 日简单移动平均线为 629.36 美元。</p>
</div><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the company earned $2.80 EPS. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.</p>
<div class="lb-trans"><p>IDEXX Laboratories (NASDAQ:IDXX - 获取免费报告) 最近在 11 月 3 日发布了季度财报。该公司报告每股收益 (EPS) 为 3.22 美元，超出市场共识预期的 3.14 美元，超出 0.08 美元。IDEXX Laboratories 的股本回报率为 67.78%，净利润率为 24.65%。该公司本季度的收入为 11.1 亿美元，而市场共识预期为 10.7 亿美元。在去年同期，该公司每股收益为 2.80 美元。与去年同期相比，该公司的季度收入增长了 13.3%。IDEXX Laboratories 已将其 2025 财年的指引设定为每股收益 12.810-13.010 美元。卖方分析师预测 IDEXX Laboratories, Inc. 今年将发布 11.93 美元的每股收益。</p>
</div><h2>Insider Activity at IDEXX Laboratories</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 的内部活动</h2>
</div><p>In related news, EVP Nimrata Hunt sold 9,425 shares of the firm's stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares of the company's stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.98% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Nimrata Hunt 于 11 月 7 日星期五出售了 9,425 股公司的股票。该股票以平均价格 703.34 美元出售，总价值为 6,628,979.50 美元。交易完成后，该执行副总裁持有 21,149 股公司股票，价值约为 14,874,937.66 美元。这笔交易代表其持股减少了 30.83%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有公司 0.98% 的股票。</p>
</div><h2>About IDEXX Laboratories</h2>
<div class="lb-trans"><h2>关于 IDEXX Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.</p>
<div class="lb-trans"><p>IDEXX Laboratories, Inc NASDAQ: IDXX 是一家全球开发、制造和提供诊断产品和服务的公司，主要面向动物健康、水质检测和食品安全市场。公司总部位于缅因州韦斯特布鲁克，提供临床诊断仪器、消耗品、参考实验室测试和实践管理工具，支持全球的兽医、畜牧和乳制品生产商以及公用事业和食品生产商。</p>
</div><p>IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.</p>
<div class="lb-trans"><p>IDEXX 的产品组合包括用于兽医诊所快速诊断的即时检测和免疫测定、临床化学和血液学分析仪、自动化尿液分析系统以及数字诊断解决方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than IDEXX Laboratories</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump Did WHAT??</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 IDEXX Laboratories 更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>在 1 月 1 日之前投资 1,000 美元于此股票 [不是 NVDA]</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>特朗普做了什么？？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding IDXX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对冲基金持有 IDXX 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 IDEXX Laboratories, Inc.（NASDAQ:IDXX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IDXX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
</div><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 IDEXX Laboratories 并不在名单上。</p>
</div><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IDEXX Laboratories 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Friedenthal Financial 购买了 IDEXX 实验室公司新的股份 $IDXX